Cullen Frost Bankers Inc. Has $80,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Cullen Frost Bankers Inc. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 97.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 534 shares of the medical research company's stock after selling 18,748 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in Charles River Laboratories International were worth $80,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CRL. Cibc World Markets Corp lifted its position in shares of Charles River Laboratories International by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company's stock worth $1,493,000 after buying an additional 1,124 shares during the period. Royal London Asset Management Ltd. lifted its position in shares of Charles River Laboratories International by 6.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company's stock worth $3,032,000 after buying an additional 991 shares during the period. Quantbot Technologies LP lifted its position in shares of Charles River Laboratories International by 13.8% during the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company's stock worth $1,717,000 after buying an additional 1,131 shares during the period. American Century Companies Inc. lifted its position in shares of Charles River Laboratories International by 5.6% during the 4th quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company's stock worth $551,000 after buying an additional 157 shares during the period. Finally, Sei Investments Co. raised its position in Charles River Laboratories International by 6.1% in the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company's stock valued at $124,394,000 after purchasing an additional 38,827 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Down 1.4%

Shares of Charles River Laboratories International stock traded down $2.15 during trading on Friday, reaching $154.55. 493,642 shares of the company were exchanged, compared to its average volume of 1,037,944. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The business has a 50-day moving average price of $147.42 and a 200-day moving average price of $150.57. The firm has a market capitalization of $7.59 billion, a price-to-earnings ratio of -237.77, a P/E/G ratio of 5.23 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period in the previous year, the firm earned $2.27 earnings per share. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on CRL shares. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. Finally, TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $174.54.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).